Combination of microtubule targeting agents with other antineoplastics for cancer treatment

Tingting Liang; Lu Lu; Xueting Song; Jianguo Qi; Jianhong Wang

doi:10.1016/j.bbcan.2022.188777

Combination of microtubule targeting agents with other antineoplastics for cancer treatment

Biochim Biophys Acta Rev Cancer. 2022 Sep;1877(5):188777. doi: 10.1016/j.bbcan.2022.188777. Epub 2022 Aug 10.

Authors

Tingting Liang¹, Lu Lu², Xueting Song³, Jianguo Qi⁴, Jianhong Wang⁵

Affiliations

¹ Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng, Henan Province 475004, China. Electronic address: ltt910710@henu.edu.cn.
² Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng, Henan Province 475004, China. Electronic address: lulu@henu.edu.cn.
³ Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng, Henan Province 475004, China. Electronic address: sxt1997@henu.edu.cn.
⁴ Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng, Henan Province 475004, China. Electronic address: qijianguo@henu.edu.cn.
⁵ Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, Kaifeng, Henan Province 475004, China. Electronic address: hdky@henu.edu.cn.

PMID: 35963551
DOI: 10.1016/j.bbcan.2022.188777

Abstract

Microtubule targeting agents (MTAs) have attracted extensive attention for cancer treatment. However, their clinical efficacies are limited by intolerable toxicities, inadequate efficacy and acquired multidrug resistance. The combination of MTAs with other antineoplastics has become an efficient strategy to lower the toxicities, overcome resistance and improve the efficacies for cancer treatment. In this article, we review the combinations of MTAs with some other anticancer drugs, such as cytotoxic agents, kinases inhibitors, histone deacetylase inhibitors, immune checkpoints inhibitors, to overcome these obstacles. We strongly believe that this review will provide helpful information for combination therapy based on MTAs.

Keywords: Antitumor; Combination therapy; Microtubule targeting agents; Resistance; Toxicity.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Cytotoxins / pharmacology
Cytotoxins / therapeutic use
Histone Deacetylase Inhibitors / pharmacology
Histone Deacetylase Inhibitors / therapeutic use
Humans
Microtubules
Neoplasms* / drug therapy

Substances

Antineoplastic Agents
Cytotoxins
Histone Deacetylase Inhibitors